ArticleThe Journal of clinical investigation2023
Adverse outcomes in SARS-CoV-2-infected pregnant mice are gestational age-dependent and resolve with antiviral treatment.
Article in The Journal of clinical investigation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 19 citations in OpenAlex.
- Trimester-dependent vertical transmission of H5N1 influenza virus through placental and mammary routes impairs offspring development.Nature communications · 2026Article
- Maternal High Fat Diet and Acute Viral Mimic Exposure Impact Placental Inflammation, Lipid Peroxidation and Cellular Proliferation-to-Death Ratio Across Mouse Pregnancy.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026Article
- Influenza B virus suppression of Chromosome Y-linked genes increases pulmonary virus replication and disease severity in male mice.Research square · 2026Article
- Mild SARS-CoV-2 maternal infection in mice induces transient offspring neurodevelopmental aberrance.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Type I interferon controls vertical transmission and fetoplacental infection of Oropouche virus.iScience · 2026Article
- Dipeptidylpeptidase 4 inhibition attenuates gestational pathologies via immune homeostasis restoration in the pulmonary-uterine axis.Nature communications · 2026Article
- COVID-19-related inflammation of the placenta impedes fetal development in pregnant hamsters.Nature communications · 2026Article
- The Timing of Intrauterine Exposure to Maternal SARS-CoV-2 Infection Impacts Neurodevelopment and Growth Trajectories During the First Year of Life.Journal of clinical medicine · 2026Article
- Adverse events associated with COVID-19 vaccination or diagnosis among pregnant and non-pregnant women in the United States, 2021-2022.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2025Article
- Mechanisms of sex differences in acute and long COVID sequelae in mice.bioRxiv : the preprint server for biology · 2025Article
- Pregnancy reduces COVID-19 vaccine immunity against novel variants.NPJ vaccines · 2025Article
- Is maternal SARS-CoV-2 infection in the first trimester associated with congenital heart defects?Frontiers in pediatrics · 2025Article
- Pathogenesis of viral infections during pregnancy.Clinical microbiology reviews · 2024Review
- Prenatal SARS-CoV-2 infection results in neurodevelopmental and behavioral outcomes in mice.JCI insight · 2024Article
- Article
Corrections and comments
- Update of
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
Abstract
SARS-CoV-2 infection during pregnancy is associated with severe COVID-19 and adverse fetal outcomes, but the underlying mechanisms remain poorly understood. Moreover, clinical studies assessing therapeutics against SARS-CoV-2 in pregnancy are limited. To address these gaps, we developed a mouse model of SARS-CoV-2 infection during pregnancy. Outbred CD1 mice were infected at E6, E10, or E16 with a mouse-adapted SARS-CoV-2 (maSCV2) virus. Outcomes were gestational age-dependent, with greater morbidity, reduced antiviral immunity, greater viral titers, and impaired fetal growth and neurodevelopment occurring with infection at E16 (third trimester equivalent) than with infection at either E6 (first trimester equivalent) or E10 (second trimester equivalent). To assess the efficacy of ritonavir-boosted nirmatrelvir, which is recommended for individuals who are pregnant with COVID-19, we treated E16-infected dams with mouse-equivalent doses of nirmatrelvir and ritonavir. Treatment reduced pulmonary viral titers, decreased maternal morbidity, and prevented offspring growth restriction and neurodevelopmental impairments. Our results highlight that severe COVID-19 during pregnancy and fetal growth restriction is associated with heightened virus replication in maternal lungs. Ritonavir-boosted nirmatrelvir mitigated maternal morbidity along with fetal growth and neurodevelopment restriction after SARS-CoV-2 infection. These findings prompt the need for further consideration of pregnancy in preclinical and clinical studies of therapeutics against viral infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.